Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7713683 | 0.86 | — | — | |
| SCHEMBL7145610 | 0.82 | SIGMAR1 (0.39) | SLC6A2SLC6A4OPRD1SIGMAR1MEN1 | |
| SCHEMBL5789735 | 0.79 | SIGMAR1 (0.47) | SLC6A2SLC6A4OPRD1SIGMAR1 | |
| SCHEMBL841129 | 0.77 | — | — | |
| SCHEMBL20458479 | 0.76 | SLC6A4 (0.34) | SLC6A2SLC6A4OPRD1SIGMAR1MEN1 | |
| SCHEMBL6556075 | 0.75 | SLC6A4 (0.36) | SLC6A2SLC6A4OPRD1SIGMAR1MEN1 | |
| SCHEMBL1262872 | 0.75 | FDPS (0.36) | SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL510134 | 0.75 | SLC6A2 (0.39) | SLC6A2SLC6A4OPRD1SIGMAR1MEN1 | |
| SCHEMBL2748230 | 0.73 | HTR1A (0.34) | OPRD1SIGMAR1CHRM5CHRM3OPRM1 | |
| SCHEMBL5066970 | 0.73 | SLC6A4 (0.35) | SLC6A2SLC6A4OPRD1SIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106928150-B | Acrylamide aniline derivative and pharmaceutical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2020-07-31 | — | — | CN | disclosed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | disclosed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| US-8211925-B2 | Benzamide glucokinase activators | TRANSTECH PHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-7084169-B2 | Aminoalkoxyindoles and methods of use | ROCHE PALO ALTO LLC (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1569638-A1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-07 | — | — | EP | disclosed |
| US-20040132799-A1 | Aminoalkoxyindoles and methods of use | ROCHE PALO ALTO LLC (US) | 2004-07-08 | — | — | US | disclosed |
| WO-2004050085-A1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
| US-6617456-B1 | Aminoalkoxy- or hydroxyalkoxy- camptothecin compound that can be bound to a polysaccharide having carboxyl groups via an amino acid or a peptide group; antitumor agents | TANABE SEIYAKU CO., LTD. (JP) | 2003-09-09 | — | — | US | disclosed |
| US-6512118-B1 | Pharmaceutically acceptable salt thereof show excellent antitumor activities against various tumors, especially they show excellent therapeutic effects on solid tumors such as pulmonary cancer, uterine cancer, ovarian cancer, breast | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-28 | — | — | US | disclosed |
| WO-2002087587-A2 | 4-AMINOSULFONYLQUINAZOLINES AND -QUINOLINES AS TYROSINE KINASE INHIBITORS | CELLTECH R & D LIMITED (GB) | 2002-11-07 | — | — | WO | disclosed |
| EP-0781781-B1 | Camptothecin derivatives | TANABE SEIYAKU CO (JP) | 2001-10-10 | — | — | EP | disclosed |
| US-5892043-A | MIXTURE WITH POLYSACCHARIDE AND PEPTIDE; ANTITUMOR AGENT | TANABE SEIYAKU CO., LTD. (JP) | 1999-04-06 | — | — | US | disclosed |
| EP-0781781-A2 | Camptothecin derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1997-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | SLC6A2 844/4885SLC6A4 948/4885OPRD1 283/4885 |
| US-20040132799-A1 | Aminoalkoxyindoles and methods of use | HTR3C, HTR2C, CYP3A5 | SLC6A2 161/4885SLC6A4 64/4885OPRD1 80/4885 |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HRH3, HRH2, HRH4 | SLC6A2 1574/4885SLC6A4 1095/4885OPRD1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.